🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. Mixed salts of a single-entity amphetamine (ADDERALL XR)

    Takeda

    ADHD

    phase 3 small molecule completed

    1 trial

  2. Motesanib

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule terminated

    1 trial

  3. NE-58095 IR

    Takeda

    Involutional Osteoporosis

    phase 3 small molecule completed

    1 trial

  4. NPSP558

    Takeda

    Hypoparathyroidism

    phase 3 small molecule completed

    3 trials

  5. Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    4 trials

  6. OBI-1

    Takeda

    Acquired Hemophilia A

    phase 3 mab completed

    1 trial

  7. OBI-1

    Takeda

    Hemophilia A

    phase 3 mab terminated

    1 trial

  8. Ontamalimab

    Takeda

    Crohn's Disease

    phase 3 mab terminated

    3 trials

  9. Ontamalimab

    Takeda

    Ulcerative Colitis

    phase 3 small molecule terminated

    3 trials

  10. Oral Budesonide Suspension (OBS)

    Takeda

    Eosinophilic Esophagitis (EoE)

    phase 3 small molecule completed

    2 trials

  11. Orteronel

    Takeda

    Prostate Cancer

    phase 3 small molecule completed

    3 trials

  12. Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for TAK-279 Dose A, ZASOCITINIB, ZASOCITINIB, Matching Placebo for TAK-279 Dose B, Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for Apremilast, Otezla 10mg, 20mg, 30 mg film-coated tablets

    Takeda

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  13. Otezla 10mg, 20mg, 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, Apremilast placebo (same excipient as over-encapsulated Otezla), Otezla 10mg, 20mg, 30 mg film-coated tablets, ZASOCITINIB, Otezla 30 mg film-coated tablets, TAK-279 placebo (same excipient as TAK-279)

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  14. Otezla 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, TAK-279 placebo (same excipient as TAK-279), Otezla 10mg, 20mg, 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, Apremilast placebo (same excipient as over-encapsulated Otezla), ZASOCITINIB

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  15. PEGylated Recombinant Factor VIII

    Takeda

    Hemophilia A

    phase 3 mab completed

    2 trials

  16. PEGylated Recombinant factor VIII (rFVIII)

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial

  17. PONATINIB, PONATINIB, Ponatinib, IMATINIB, IMATINIB

    Takeda

    Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  18. PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda

    Active Ulcerative Colitis (UC) or Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  19. PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda

    Moderately to severely active Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  20. PREDNISONE, Entyvio 300 mg powder for concentrate for solution for infusion, BUDESONIDE

    Takeda

    Moderately to severely active Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  21. PTH/Calcium

    Takeda

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  22. Pantoprazole

    Takeda

    GERD

    phase 3 small molecule completed

    1 trial

  23. Pantoprazole

    Takeda

    Gastroesophageal Reflux Disease (GERD)

    phase 3 small molecule completed

    2 trials

  24. Parathyroid Hormone (PTH)

    Takeda

    Osteoporosis

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources